Danaher
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It's Moving
Danaher is catching a lift as analysts stay constructive on a recovery in life sciences and diagnostics.
- Analysts remain upbeat on DHR’s medium-term outlook, signaling that investors are still betting on a rebound in core end markets rather than a one-off event.
- The stock is benefiting from the view that easing pressure in biotech spending and diagnostics demand could support steadier revenue trends through 2026.
- Recent commentary suggests the market is rewarding Danaher’s defensive growth profile, with investors favoring companies seen as resilient if macro conditions stay uneven.
Danaher is catching a lift as analysts stay constructive on a recovery in life sciences and diagnostics.
- Analysts remain upbeat on DHR’s medium-term outlook, signaling that investors are still betting on a rebound in core end markets rather than a one-off event.
- The stock is benefiting from the view that easing pressure in biotech spending and diagnostics demand could support steadier revenue trends through 2026.
- Recent commentary suggests the market is rewarding Danaher’s defensive growth profile, with investors favoring companies seen as resilient if macro conditions stay uneven.
When is the next earnings date for Danaher (DHR)?
Danaher (NYSE: DHR) reported its Q1 2026 earnings on April 21, 2026. With that release now complete, the next earnings date is expected on or around July 22, 2026, covering the second quarter ending June 2026, consistent with the company's historical quarterly pattern. Investors should monitor official channels for any updates to the schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher Corp. stock with a target price of $259.6, indicating potential growth.
Financial Health
Danaher Corp. is performing well, with strong revenue, cash flow, and profit margins.
Dividend
Danaher Corp.'s low dividend yield of 0.68% means it may not be ideal for dividend-seeking investors. If you invested $1000, you would be paid $6.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring DHR
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketAcquirer's Engine
Invest in companies with proven expertise in growth-by-acquisition. These carefully selected stocks represent businesses with exceptional management teams that consistently buy their way to market leadership and enhanced profitability through strategic M&A.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
